Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer’s disease

Huali Yang; Pei Cai; Qiaohong Liu; Xuelian Yang; Siqiang Fang; Yan-Wei Tang; Cheng Wang; Xiaobing Wang; Ling‐Yi Kong

doi:10.1016/j.bmc.2017.08.048

ScienceGate Book Chapters

JOURNAL ARTICLE

Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer’s disease

Huali Yang Pei Cai Qiaohong Liu Xuelian Yang Siqiang Fang Yan-Wei Tang Cheng Wang Xiaobing Wang Ling‐Yi Kong

Year: 2017 Journal: Bioorganic & Medicinal Chemistry Vol: 25 (21)Pages: 5917-5928 Publisher: Elsevier BV

DOI: 10.1016/j.bmc.2017.08.048

Get Full-Text PDF Get Analytical Report

Keywords:

Chemistry Neuroprotection Trolox Antioxidant Monoamine oxidase Pharmacology ABTS IC50 DPPH Lead compound Potency Monoamine oxidase B In vitro Biochemistry Enzyme

Metrics

Cited By

1.73

FWCI (Field Weighted Citation Impact)

Refs

0.81

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Cholinesterase and Neurodegenerative Diseases

Health Sciences → Medicine → Pharmacology

Alzheimer's disease research and treatments

Health Sciences → Medicine → Physiology

Medicinal Plants and Neuroprotection

Health Sciences → Medicine → Complementary and alternative medicine

Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer’s disease

Metrics

Citation History

Topics

Related Documents

Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer’s disease

Tacrine-hydroxamate derivatives as multitarget-directed ligands for the treatment of Alzheimer’s disease: Design, synthesis, and biological evaluation

Design, synthesis, and evaluation of multitarget-directed ligands against Alzheimer’s disease based on the fusion of donepezil and curcumin

Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer’s Disease

New chiral melatonin-derivatives as multitarget directed ligands to treat Alzheimer’s disease.